X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (23) 23
index medicus (23) 23
male (17) 17
middle aged (17) 17
female (15) 15
aged (14) 14
adult (13) 13
hematology, oncology and palliative medicine (13) 13
hematology (10) 10
aged, 80 and over (8) 8
oncology (8) 8
treatment outcome (8) 8
adolescent (6) 6
analysis (6) 6
article (6) 6
history (6) 6
risk (6) 6
therapy (6) 6
abridged index medicus (5) 5
antineoplastic agents - therapeutic use (5) 5
dasatinib (5) 5
leukemia (5) 5
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (5) 5
leukemia, myeloid, acute - drug therapy (5) 5
risk factors (5) 5
young adult (5) 5
antineoplastic agents - administration & dosage (4) 4
cancer (4) 4
care and treatment (4) 4
chemotherapy (4) 4
clinical trials (4) 4
disease-free survival (4) 4
diseases (4) 4
drug therapy (4) 4
follow-up (4) 4
historia (4) 4
medicine (4) 4
medicine, general & internal (4) 4
mutation (4) 4
recurrence (4) 4
relapse (4) 4
research (4) 4
resistance (4) 4
studies (4) 4
bone marrow (3) 3
cardiovascular disease (3) 3
chronic myelogenous leukemia (3) 3
cytarabine - administration & dosage (3) 3
diagnosis (3) 3
drug dosages (3) 3
education (3) 3
follow-up studies (3) 3
hemic and lymphatic diseases (3) 3
imatinib (3) 3
imatinib mesylate - administration & dosage (3) 3
imidazoles - administration & dosage (3) 3
inhibitor (3) 3
internal medicine (3) 3
kinases (3) 3
leukemia, myelogenous, chronic, bcr-abl positive - genetics (3) 3
leukemia, myeloid, acute - genetics (3) 3
leukemia, myeloid, chronic-phase - drug therapy (3) 3
management (3) 3
maximum tolerated dose (3) 3
medicine & public health (3) 3
mexico history (3) 3
mortality (3) 3
mutations (3) 3
patients (3) 3
prevention (3) 3
pyridazines - administration & dosage (3) 3
remission induction (3) 3
retrospective studies (3) 3
survival analysis (3) 3
achievement (2) 2
acute myelogenous leukemia (2) 2
adult patients (2) 2
antineoplastic combined chemotherapy protocols (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
bibliografía (2) 2
bibliography (2) 2
bosutinib (2) 2
cells (2) 2
chemistry, multidisciplinary (2) 2
chromosomes (2) 2
clinical trials as topic (2) 2
colecciones de escritos (2) 2
combination (2) 2
cytarabine (2) 2
demographic aspects (2) 2
diabetes (2) 2
diabetis (2) 2
dosage and administration (2) 2
early molecular response (2) 2
eroberung (2) 2
evolution (2) 2
expression (2) 2
failure (2) 2
fda approval (2) 2
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (52) 52
Spanish (22) 22
Portuguese (5) 5
Catalan (2) 2
French (1) 1
German (1) 1
Latin (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 15, pp. 1547 - 1555
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 9, pp. 1025 - 1036
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 612 - 621
Journal Article
Lancet Haematology, The, ISSN 2352-3026, 2015, Volume 2, Issue 3, pp. e118 - e128
Journal Article
Journal Article
Journal Article
Lancet Haematology, The, ISSN 2352-3026, 2016, Volume 3, Issue 12, pp. e581 - e591
Journal Article
The Lancet, ISSN 0140-6736, 08/2018, Volume 392, Issue 10147, pp. 593 - 606
For several decades, few substantial therapeutic advances have been made for patients with acute myeloid leukaemia. However, since 2017 unprecedented growth... 
NEWLY-DIAGNOSED AML | ADULT PATIENTS | MEDICINE, GENERAL & INTERNAL | OLDER PATIENTS | RANDOMIZED PHASE-III | MULTIPARAMETER FLOW-CYTOMETRY | CLONAL HEMATOPOIESIS | RISK MYELODYSPLASTIC SYNDROME | HIGH-DOSE CYTARABINE | STEM-CELL TRANSPLANTATION | MINIMAL RESIDUAL DISEASE | Recurrence | Antibodies, Monoclonal, Humanized - therapeutic use | Risk Assessment | Genomics | Humans | Risk Factors | Hematopoietic Stem Cell Transplantation | Staurosporine - analogs & derivatives | Antineoplastic Agents - therapeutic use | Consolidation Chemotherapy | Remission Induction | Cytarabine - administration & dosage | Patient Selection | Leukemia, Myeloid, Acute - diagnosis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Staurosporine - therapeutic use | Leukemia, Myeloid, Acute - drug therapy | Leukemia, Myeloid, Acute - therapy | Aminoglycosides - therapeutic use | Leukemia, Myeloid, Acute - genetics | Strategic planning (Business) | Drug approval | Drugs | Pathogenesis | Leukemia | Clinical trials | Cytotoxicity | Genomes | Drug development | Regulatory approval | Older people | Risk assessment | Bone marrow | Drug dosages | Age | Medical research | Hematology | Cloning | Health risks | FDA approval | Patients | Chemotherapy | Medical prognosis | Response rates | Stem cells | Mutation | Risk management | Tumors
Journal Article